OIG report: FDA review of generic ANDAs comes up short
OIG has released a report on FDA's generic drug review process.
The Department of Health & Human Services Office of Inspector General (OIG) has released the Food & Drug Administration's Generic Drug Review Process report. Among the findings: The FDA approved or tentatively approved 4% of original Abbreviated New Drug Applications (ANDAs) under review in 2006; the remaining 96% did not meet review standards and were disapproved; the FDA exceeded the 180-day review requirement for nearly half of original ANDAs under review in 2006 because Chemistry reviews exceeded 180 days; Microbiology, Bioequivalence, and Labeling reviews of original ANDAs generally exceeded 180 days in 2006.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
